Autologous stem cell transplantation in the treatment of multiple myeloma with 17p deletion

2020
journal article
article
5
cris.lastimport.wos2024-04-10T00:24:48Z
dc.abstract.enIntroduction Deletion of chromosome 17p [del(17p)] in patients with multiple myeloma is associated with a poor prognosis. High‑dose chemotherapy followed by autologous stem cell transplantation (ASCT) remains the standard of treatment in this population. Objectives The aim of the study was to compare the treatment outcomes with high‑dose chemotherapy and ASCT with standard treatment in patients with del(17p). Patients and methods We collected data from 12 Polish centers between 2011 and 2017. The records of 97 patients with p53 deletion were assessed, including 29 individuals treated with ACST and 68 receiving standard treatment alone. Results During the follow‑up, 45 patients died and the overall survival (OS) for the whole group was 33 months (range, 1–66 months), with a median progression‑free survival (PFS) of 13 months (range, 1–46 months). The prognostic factors of OS in a multivariable analysis were calcium levels at diagnosis within the reference range (hazard ratio [HR], 0.24; 95% CI, 0.12–0.48) and at least partial remission achieved after the first‑line treatment (HR, 0.25; 95% CI, 0.12–0.51). Treatment with ASCT was an important factor in improving survival (HR, 3.23; 95% CI, 1.52–6.84). Abnormal kidney function at the time of diagnosis reduced the PFS (HR, 0.46; 95% CI, 0.22–0.94). When the analysis was limited only to patients who could be candidates for ASCT, the survival benefit of the procedure was lost (P = 0.21). Conclusions Patients with multiple myeloma with del(17p) do not benefit from high‑dose chemotherapy followed by ACST.pl
dc.affiliationWydział Lekarski : Klinika Hematologiipl
dc.cm.date2020-12-02
dc.cm.id98330
dc.contributor.authorCzyż, Jarosławpl
dc.contributor.authorJurczyszyn, Artur - 255153 pl
dc.contributor.authorSzudy-Szczyrek, Anetapl
dc.contributor.authorKoclęga, Ananpl
dc.contributor.authorJachalska, Annapl
dc.contributor.authorDzierżak-Miotła, Monikapl
dc.contributor.authorPuła, Bartoszpl
dc.contributor.authorJamroziak, Krzysztofpl
dc.contributor.authorUsnarska-Zubkiewicz, Lidiapl
dc.contributor.authorGil, Lidiapl
dc.contributor.authorJarosińska-Romejko, Joannapl
dc.contributor.authorWaszczuk-Gajda, Annapl
dc.date.accession2020-07-09pl
dc.date.accessioned2020-12-02T10:25:24Zpl
dc.date.available2020-12-02T10:25:24Zpl
dc.date.issued2020pl
dc.date.openaccess0
dc.description.accesstimew momencie opublikowania
dc.description.number2pl
dc.description.physical106-111pl
dc.description.points100pl
dc.description.versionostateczna wersja wydawcy
dc.description.volume130pl
dc.identifier.doi10.20452/pamw.15139pl
dc.identifier.eissn1897-9483pl
dc.identifier.issn0032-3772pl
dc.identifier.projectROD UJ / OPpl
dc.identifier.urihttps://ruj.uj.edu.pl/xmlui/handle/item/257075
dc.identifier.weblinkhttps://www.mp.pl/paim/issue/article/15139pl
dc.languageengpl
dc.language.containerengpl
dc.rightsUdzielam licencji. Uznanie autorstwa - Użycie niekomercyjne - Na tych samych warunkach 4.0 Międzynarodowa*
dc.rights.licenceCC-BY-NC-SA
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/legalcode.pl*
dc.share.typeotwarte czasopismo
dc.subject.enautologous stem cell transplantationpl
dc.subject.enmultiple myelomapl
dc.subject.en17p deletionpl
dc.subtypeArticlepl
dc.titleAutologous stem cell transplantation in the treatment of multiple myeloma with 17p deletionpl
dc.title.journalPolskie Archiwum Medycyny Wewnętrznej = Polish Archives of Internal Medicinepl
dc.typeJournalArticlepl
dspace.entity.typePublication
cris.lastimport.wos
2024-04-10T00:24:48Z
dc.abstract.enpl
Introduction Deletion of chromosome 17p [del(17p)] in patients with multiple myeloma is associated with a poor prognosis. High‑dose chemotherapy followed by autologous stem cell transplantation (ASCT) remains the standard of treatment in this population. Objectives The aim of the study was to compare the treatment outcomes with high‑dose chemotherapy and ASCT with standard treatment in patients with del(17p). Patients and methods We collected data from 12 Polish centers between 2011 and 2017. The records of 97 patients with p53 deletion were assessed, including 29 individuals treated with ACST and 68 receiving standard treatment alone. Results During the follow‑up, 45 patients died and the overall survival (OS) for the whole group was 33 months (range, 1–66 months), with a median progression‑free survival (PFS) of 13 months (range, 1–46 months). The prognostic factors of OS in a multivariable analysis were calcium levels at diagnosis within the reference range (hazard ratio [HR], 0.24; 95% CI, 0.12–0.48) and at least partial remission achieved after the first‑line treatment (HR, 0.25; 95% CI, 0.12–0.51). Treatment with ASCT was an important factor in improving survival (HR, 3.23; 95% CI, 1.52–6.84). Abnormal kidney function at the time of diagnosis reduced the PFS (HR, 0.46; 95% CI, 0.22–0.94). When the analysis was limited only to patients who could be candidates for ASCT, the survival benefit of the procedure was lost (P = 0.21). Conclusions Patients with multiple myeloma with del(17p) do not benefit from high‑dose chemotherapy followed by ACST.
dc.affiliationpl
Wydział Lekarski : Klinika Hematologii
dc.cm.date
2020-12-02
dc.cm.id
98330
dc.contributor.authorpl
Czyż, Jarosław
dc.contributor.authorpl
Jurczyszyn, Artur - 255153
dc.contributor.authorpl
Szudy-Szczyrek, Aneta
dc.contributor.authorpl
Koclęga, Anan
dc.contributor.authorpl
Jachalska, Anna
dc.contributor.authorpl
Dzierżak-Miotła, Monika
dc.contributor.authorpl
Puła, Bartosz
dc.contributor.authorpl
Jamroziak, Krzysztof
dc.contributor.authorpl
Usnarska-Zubkiewicz, Lidia
dc.contributor.authorpl
Gil, Lidia
dc.contributor.authorpl
Jarosińska-Romejko, Joanna
dc.contributor.authorpl
Waszczuk-Gajda, Anna
dc.date.accessionpl
2020-07-09
dc.date.accessionedpl
2020-12-02T10:25:24Z
dc.date.availablepl
2020-12-02T10:25:24Z
dc.date.issuedpl
2020
dc.date.openaccess
0
dc.description.accesstime
w momencie opublikowania
dc.description.numberpl
2
dc.description.physicalpl
106-111
dc.description.pointspl
100
dc.description.version
ostateczna wersja wydawcy
dc.description.volumepl
130
dc.identifier.doipl
10.20452/pamw.15139
dc.identifier.eissnpl
1897-9483
dc.identifier.issnpl
0032-3772
dc.identifier.projectpl
ROD UJ / OP
dc.identifier.uri
https://ruj.uj.edu.pl/xmlui/handle/item/257075
dc.identifier.weblinkpl
https://www.mp.pl/paim/issue/article/15139
dc.languagepl
eng
dc.language.containerpl
eng
dc.rights*
Udzielam licencji. Uznanie autorstwa - Użycie niekomercyjne - Na tych samych warunkach 4.0 Międzynarodowa
dc.rights.licence
CC-BY-NC-SA
dc.rights.uri*
http://creativecommons.org/licenses/by-nc-sa/4.0/legalcode.pl
dc.share.type
otwarte czasopismo
dc.subject.enpl
autologous stem cell transplantation
dc.subject.enpl
multiple myeloma
dc.subject.enpl
17p deletion
dc.subtypepl
Article
dc.titlepl
Autologous stem cell transplantation in the treatment of multiple myeloma with 17p deletion
dc.title.journalpl
Polskie Archiwum Medycyny Wewnętrznej = Polish Archives of Internal Medicine
dc.typepl
JournalArticle
dspace.entity.type
Publication

* The migration of download and view statistics prior to the date of April 8, 2024 is in progress.

Views
1
Views per month
Views per city
Shanghai
1
Downloads
jurczyszyn_et-al_autologous_stem_cell_transplantation_in_the_treatment_of_multiple_myeloma_2020.pdf
5